According to filings with the U.S. Securities and Exchange Commission, Sinopia Biosciences is raising up to $4,253,094.00 in new funding. The federal securities law requires the notice to be filed by companies that have sold securities without registration under the Securities Act of 1933 in an offering made under Rule 504 or 506 of Regulation D or Section 4(a)(5) of the Securities Act. A company must file this notice within 15 days after the first sale of securities in the offering. For this purpose, the date of first sale is the date on which the first investor is irrevocably contractually committed to invest. Each issuer of securities that sells its securities in reliance on an exemption provided in Regulation D or Section 4(a)(5) of the Securities Act of 1933 must file this notice containing the information requested with the U.S. Securities and Exchange Commission (SEC) and with the state(s) requiring it. If more than one issuer has sold its securities in the same transaction, all issuers should be identified in this filing with the SEC.

About Sinopia Biosciences
Sinopia Biosciences is a privately held biotechnology company that uses its proprietary LEADS (LEarn And DiScover) computational drug discovery platform to advance novel therapeutics for complex diseases. Its platform integrates high-throughput omics data, artificial intelligence and machine learning, and network analyses to decode disease biology and identify first-in-class therapeutic targets and drug candidates, with an initial focus on neurology, oncology, genetic diseases, and particularly Parkinsons disease. Sinopias lead program, SB-0110, is a first-in-class small molecule positive allosteric modulator of protein kinase A II (PKA-II) designed to treat both Parkinsons disease and levodopa-induced dyskinesia, aiming to restore brain health and change the course of the disease. The company emphasizes combining data science innovation, deep biological insight, and a strong commitment to patients, and is headquartered at JLABS in San Diego, California. Sinopia has also entered into collaborations, such as a target discovery partnership with Ono Pharmaceutical focused on rare metabolic disorders with significant unmet medical need, underscoring its role as a specialized, AI-driven drug discovery innovator.

To learn more, visit https://www.sinopiabio.com/
LinkedIn: https://www.linkedin.com/company/sinopiabio

Contact:
Aarash Bordbar, Interim Chief Executive Officer

SOURCE: http://www.intelligence360.io
Copyright (c) 2026 SI360 Inc. All rights reserved.